Sales markets: Western Europe | Eastern Europe | Middle East | Asia | Australia | North America | Africa | Central/South America

About us

Polpharma Group is a high quality European pharma and biotech manufacturer and a reputable business partner for pharmaceutical companies worldwide. We grow our presence through B2B activities, including API custom development and manufacturing in our cGMP-compliant and FDA-approved facility, out-licensing of vertically integrated solutions from API to finished formulation, and contract manufacturing services covering a wide variety of solid and liquid forms. We are also a fully integrated, state-of-the-art biotechnology CDMO player mastering all steps of the industrial value chain from cell line generation via process and product development to biopharmaceutical GMP manufacturing from clinical to commercial scale.




Read more

Meet us at

24 apr 2018

CPhI North America 2018

24-26 April, 2018 Philadelphia, USA Visit us at stand 1049 Book a meeting See our Exhibitor Profile
20 jun 2018

CPhI & PMEC China 2018

20 - 22 June, 2018 Shanghai, China Visit us at stand E1N28 Book a meeting See our Exhibitor Profile

News about Polpharma

Polpharma B2B around the World 2018!

2 Jan 2018

Polpharma B2B around the World 2018!

In 2018, we will travel around the world participating in major business events and face-to-face meetings in order to propose the best solutions to your needs and discover further business opportunities. There will be many occasions to tighten our partnership and help your business grow.

To discover more about Polpharma B2B, contact us today.


Read more

19 Dec 2017

The next Polish GMP inspections (MPI) at API plant finished with positive result!

Recently, the Polish Authorities (MPI, Main Pharmaceutical Inspectorate) conducted two inspections at Polpharma API Plant.

Both inspections finished with a positive result, the inspectors will recommend the issue of GMP certificates for all the substances evaluated. This was a further acknowledgment that the API Plant meets GMP requirements, and the certificate makes it possible to sell our products around the world.
This is the best confirmation that We deliver quality.

In September, our recently developed active substances were accepted by MPI:
• Bazedoxifene Acetate
• Brexpiprazole
• Aripiprazole Monohydrate

as well as:
• Piracetam
• Carvedilol
• Tolterodine tartrate
• Carbamazepine
• Pentoxifylline

Moreover, in October MPI approved another 8 active substances from our portfolio:
• Hydrochlorothiazide
• Avanafil
• Alendronate sodium trihydrate
• Eodolac
• Ticagrelor
• Saxagliptin monohydrate
• Zolendronic acid monohydrate
• Metronizadole

Talk with our Sales Team!

Read more

7 Nov 2017

Our Sales & Marketing Experts will meet you in Moscow!

Polpharma B2B Team will be waiting for you in Moscow at 19th edition of Pharmtech&Ingredients. Do not miss opportunity to discuss about our tailor-made solutions for your business.
We are waiting for you at our booth A430, Pavilion 2, Hall 7

Read more

13 Oct 2017

Meet our Team of Experts at CPhI Worldwide 2017 in Frankfurt!

Meet our Team of Experts at CPhI Worldwide 2017! Polpharma B2B Team is looking forward to meeting you at CPhI in Frankfurt 2017! Our Team will be delighted to discuss our approach to providing solutions for you.  Let’s meet to collaborate at our booth 6 0D.30.

Read more